The medical artificial intelligence (AI) corporation MEDICAL IP officially supplied its AI-based body composition analysis software "DeepCatch" to Peking Union Medical College (PUMC), China's top hospital, on 9th. According to the company, it successfully commercialized medical AI for the first time among domestic digital healthcare corporations by supplying it to a local hospital in China.
DeepCatch automatically creates a three-dimensional (3D) digital twin of more than 100 anatomical structures from chest and abdominal CT images. The digital twin is a technology that accurately reproduces physical objects in a virtual world and predicts potential problems in reality through simulations. This technology can expand the scope from body composition analysis to disease prediction, quantification of health risk factors, and preventive medicine.
Previously, MEDICAL IP obtained medical device certification (registration number: 20252210138) from the National Medical Products Administration (NMPA) of China on 20th of last month, becoming the first medical AI specialized corporation to do so. This contract marks the first official supply case following that certification. The company explained that the delivery was made through a medical device distributor located in Jiangsu Province, China.
Peking Union Medical College is regarded as a national central hospital with the highest level of authority in the treatment of rare and severe diseases, and it is evaluated as a leading platform for the introduction of new technologies and the empirical assessment of medical policies. This contract also includes ▲ installation within the hospital ▲ user training ▲ maintenance ▲ securing brand marketing rights.
The company plans to use this as a stepping stone to expand the supply of medical AI solutions to major hospitals in China. MEDICAL IP also aims to actively collaborate with hospitals, health check-up centers, and public health institutions using its core technologies such as the AI X-ray quantification solution "DeepCatch X" and the digital anatomy education platform "MEDIP BOX."
Park Sang-jun, the CEO of MEDICAL IP, noted, "Since 2018, we have prepared to enter the Chinese market as a strategic expansion area, and this contract marks not only a corporation's achievement but also a national accomplishment, creating the first case where Korean medical AI technology has penetrated the walls of the Chinese market and is used in actual clinical settings."
He said, "There were skeptical views about entering the Chinese market, but we challenged it since 2018 and finally achieved a milestone. We will strengthen our position in the Chinese market to promote the large-scale distribution and sales of our products and accelerate the commercialization of medical AI technology."